- Home
- IMTE vs TOVX Comparison
IMTE vs TOVX Comparison
Compare IMTE & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMTE
- TOVX
- Stock Information
- Founded
- IMTE 2008
- TOVX 2001
- Country
- IMTE Malaysia
- TOVX United States
- Employees
- IMTE N/A
- TOVX N/A
- Industry
- IMTE Consumer Electronics/Appliances
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- IMTE Consumer Staples
- TOVX Health Care
- Exchange
- IMTE Nasdaq
- TOVX Nasdaq
- Market Cap
- IMTE 3.3M
- TOVX 4.5M
- IPO Year
- IMTE N/A
- TOVX 2006
- Fundamental
- Price
- IMTE $1.00
- TOVX $0.42
- Analyst Decision
- IMTE
- TOVX Hold
- Analyst Count
- IMTE 0
- TOVX 1
- Target Price
- IMTE N/A
- TOVX N/A
- AVG Volume (30 Days)
- IMTE 30.5K
- TOVX 1.2M
- Earning Date
- IMTE 10-21-2025
- TOVX 08-11-2025
- Dividend Yield
- IMTE N/A
- TOVX N/A
- EPS Growth
- IMTE N/A
- TOVX N/A
- EPS
- IMTE N/A
- TOVX N/A
- Revenue
- IMTE $123,337.00
- TOVX N/A
- Revenue This Year
- IMTE N/A
- TOVX N/A
- Revenue Next Year
- IMTE N/A
- TOVX N/A
- P/E Ratio
- IMTE N/A
- TOVX N/A
- Revenue Growth
- IMTE 4.75
- TOVX N/A
- 52 Week Low
- IMTE $0.51
- TOVX $0.37
- 52 Week High
- IMTE $3.17
- TOVX $7.15
- Technical
- Relative Strength Index (RSI)
- IMTE 46.33
- TOVX 44.90
- Support Level
- IMTE $0.92
- TOVX $0.45
- Resistance Level
- IMTE $1.02
- TOVX $0.47
- Average True Range (ATR)
- IMTE 0.06
- TOVX 0.04
- MACD
- IMTE 0.00
- TOVX 0.00
- Stochastic Oscillator
- IMTE 45.71
- TOVX 31.76
About IMTE Integrated Media Technology Limited
Integrated Media Technology Ltd is engaged in the development, sale, and distribution of autostereoscopic 3D display, 3D conversion equipment, and software, development, and sale of 3D autostereoscopic technology, and the provision of 3D consultancy services. It operates through the following segments: the sale of electronic glass, sales of air-filter products, sales of Halal products, NFT, corporate, provision of consultancy and provision of new energy products and solutions.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.